Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer

Launched by COPENHAGEN UNIVERSITY HOSPITAL AT HERLEV · Mar 27, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring new ways to predict how well patients with localized pancreatic cancer might do after surgery. Specifically, researchers want to see if certain blood tests that check for small pieces of DNA (called ctDNA and eccDNA) can help identify patients at risk for cancer returning, as well as improve overall survival rates. They are comparing these blood tests combined with imaging techniques like CT scans and endoscopic ultrasounds against standard monitoring methods after surgery to see which approach is more effective.

To participate in this study, patients need to have a confirmed diagnosis of pancreatic cancer that can be surgically removed (stages I-III) and be scheduled for surgery, with some potentially receiving chemotherapy beforehand. Another group of patients who have already had successful surgery and are cancer-free four months later may also be included. Participants in the trial can expect regular monitoring and follow-ups to track their health and response to the study procedures. It's important to note that patients with other recent cancers or those who may have difficulty attending follow-up visits may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.
• • Sub-study 2: .
• • PDAC tumor stage I-III
• • Has received intended curative resection (R0/R1) of PDAC
• • No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation
• Exclusion Criteria:
• • Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion
• • Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study